Hikma Pharmaceuticals (HKMPF) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Hikma Pharmaceuticals

    PNK: HKMPF · Real-Time Price · USD
    26.93
    0.73 (2.80%)
    At close: May 07, 2025, 12:33 PM

    Hikma Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 3.13B 2.88B 2.52B 2.55B
    Cost of Revenue
    		 1.71B 1.47B 1.25B 1.25B
    Gross Profit
    		 1.42B 1.41B 1.26B 1.3B
    Operating Income
    		 612M 367M 591M 634M
    Interest Income
    		 7.83M 7M 56M 42M
    Pretax Income
    		 455M 281M 233M 544M
    Net Income
    		 359M 190M 188M 421M
    Selling & General & Admin
    		 568M 632M 509M 488M
    Research & Development
    		 141M 149M 144M 143M
    Other Expenses
    		 94M 259M n/a n/a
    Operating Expenses
    		 803M 1.04B 976M 715M
    Interest Expense
    		 75M 90M 77M 56M
    Selling & Marketing Expenses
    		 n/a -6M n/a n/a
    Cost & Expenses
    		 2.52B 2.51B 2.23B 1.97B
    Income Tax Expense
    		 93M 89M 42M 124M
    Shares Outstanding (Basic)
    		 221.33M 223.53M 223.73M 231M
    Shares Outstanding (Diluted)
    		 223.49M 222.37M 225M 233M
    EPS (Basic)
    		 1.61 0.85 0.84 1.82
    EPS (Diluted)
    		 1.61 0.85 0.84 1.81
    EBITDA
    		 787M 791M 485M 744M
    EBIT
    		 608M 619M 292M 600M
    Depreciation & Amortization
    		 179M 172M 193M 144M

    Add to Watchlist